Hardman & Co Research: Haydale (HAYD): Exuberance, reality; enlightenment now to follow

Hardman & Co: Exuberance, reality; enlightenment now to follow

Haydale is competitively well-positioned within the nanomaterial industry, with a unique patented functionalisation process - currently focused on, but not limited to, graphene. Commercial developments for graphene and silicon carbide are progressing well and, while timings of commensurate news releases may be lagging, the long-term risk/reward balance remains favourable. The shares are attractively valued compared with their peer group, on P/NAV and EV/sales, and also on a DCF basis.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/haydale-graphene-industries-documents/26.09.18-exuberance-reality-enlightenment-now-to-follow.pdf

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.